文献速递脑血管病外科神经重症

尼莫地平与米力农在迟发性脑缺血中的作用

Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia.
PubMed 文献 · World Neurosurg · 2022-07-16

这项前瞻性观察研究纳入2020年11月至2021年6月间动脉瘤性蛛网膜下腔出血后迟发性脑缺血、仅接受动脉内尼莫地平或静脉米力农治疗的患者34例,比较临床与经颅多普勒参数;动脉内尼莫地平组死亡率显著低于静脉米力农组。

要点

  • 34例中静脉米力农组13例(38%),动脉内尼莫地平组21例(62%)。
  • 动脉内尼莫地平组死亡1/21(9%)vs 静脉米力农组4/13(23%),P=0.037。
  • 两组大脑中动脉血管痉挛的经颅多普勒效应相似,但动脉内尼莫地平随时间推移表现更优。

核心结论

  • 在这项单中心小型研究中,动脉瘤性蛛网膜下腔出血后迟发性脑缺血的管理中,动脉内尼莫地平组死亡率显著低于静脉米力农组。

研究设计与样本

  • 前瞻性观察研究,纳入2020年11月至2021年6月间动脉瘤性蛛网膜下腔出血后迟发性脑缺血、仅接受动脉内尼莫地平或静脉米力农治疗的患者,排除同时接受两种治疗或行机械血管成形术者,最终34例符合纳入标准。

主要发现

  • 静脉米力农组13/34(38%),动脉内尼莫地平组21/34(62%)。
  • 静脉米力农组 vs 动脉内尼莫地平组:中位格拉斯哥昏迷评分12 vs 13;运动反应<M6者5/13(38%)vs 5/21(24%),P=0.36;改良Fisher分级≥3者12/13(92%)vs 8/21(86%),P=0.56。
  • 动脉内尼莫地平组 vs 静脉米力农组:临床改善17/21(81%)vs 10/13(77%),P=0.77;新发梗死15/21(71%)vs 7/13(54%),P=0.29;出院回家13/21(62%)vs 6/13(46%),P=0.36;死亡1/21(9%)vs 4/13(23%),P=0.037。
  • 经颅多普勒分析显示,两种方案对大脑中动脉血管痉挛的效果相似,但动脉内尼莫地平随时间推移表现更优;组效应分析中,动脉内尼莫地平方案对大脑前动脉和大脑后动脉血管痉挛显著优于静脉米力农方案。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文称本研究为单中心小型研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The role of nimodipine and milrinone in the management of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) was studied using clinical and TCD (transcranial Doppler) parameters. METHODS: In this prospective observational study, patients with DCI after aneurysmal SAH presenting between November 2020 and June 2021 who were treated by either intra-arterial nimodipine (IAN) or intravenous milrinone (IVM) were included after excluding patients in whom both IAN and IVM had been given or mechanical angioplasty was performed. Twelve-hourly TCD was performed during the course of the therapy. Clinical improvement and the development of new brain infarcts were also assessed. A P value <0.05 was considered statistically significant. RESULTS: Thirty-four patients fulfilled the inclusion criteria (IVM, 13/34 [38%]; IAN, 21/34 [62%]); patients in the IVM group (vs. IAN group) had poorer median Glasgow Coma Scale score (12 vs. 13), poorer motor response (<M6 response, 5/13 [38%] vs. 5/21 [24%]; P = 0.36) and higher grades (modified Fisher grade ≥3) of SAH (12/13 [92%] vs. 8/21 [86%]; P = 0.56). More patients in the IAN group (vs. IVM group) showed clinical improvement (17/21 [81%] vs. 10/13 [77%]; P = 0.77), development of new infarcts (15/21 [71%] vs. 7/13 [54%]; P = 0.29] and discharged to home (13/21 [62%] vs. 6/13 [46%]; P = 0.36) with less mortality (1/21 [9%] vs. 4/13 [23%]; P = 0.037). On TCD analysis, both IAN and IVM protocols showed similar effects in middle cerebral artery vasospasm; however, IAN proved better over time. In group-effect analysis, the IAN protocol was significantly better in anterior cerebral artery and posterior cerebral artery vasospasm compared with IVM protocol. CONCLUSIONS: In this single-center small study, patients in the IAN group had significantly less mortality compared with the IVM group in the management of DCI after aneurysmal SAH.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Kotwal A, Ramalingaiah AH, Shukla D, et al. Role of Nimodipine and Milrinone in Delayed Cerebral Ischemia. World Neurosurg. 2022. PMID: 35843579. doi:10.1016/j.wneu.2022.06.150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。